STADA takes clear lead in Russian consumer healthcare sector

11 March 2020

GMP News

STADA is now the largest foreign investor in the Russian pharmaceutical industry, following the completion today of a US$ 660 million transaction for a Russian brand portfolio from Takeda and having invested in around EUR 1 billion in recent years. The transaction will enable the group to continue expanding its presence and investments in Russia.

Having closed the previously announced acquisition from Takeda, STADA has now obtained a portfolio of approximately 20 selected over-the-counter (‘OTC’) and prescription pharmaceutical assets sold in Russia, Georgia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan.

Based on data from IQVIA, including the Aqualor brand, the transaction makes STADA the clear market leader in Russia’s consumer healthcare sector with a 6.4% market share.

Peter Goldschmidt, CEO of STADA, commented:

“This is an important strategic step for STADA and positions us as the leading player in a large and expanding Russian consumer healthcare market. This transaction reflects not only our commitment to our operations in Russia, but also our successful growth journey as we continue expanding our core generics and consumer healthcare businesses internationally, both organically and through targeted business-development activities.”

The portfolio acquired from Takeda complements the existing portfolio of STADA in Russia comprising of over 150-products including medicines from more or less all therapeutic areas. This portfolio includes vitamins and food supplements, plus selected products within the cardiovascular, diabetes, general medicine, and respiratory therapeutic areas. Included in the transaction is the category-leading cardiovascular brand Cardiomagnyl, as well as the patent-protected diabetes treatment Nesina and Edarbi, an angiotensin II receptor blocker for controlling blood pressure.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more